Technologies
Aceso Therapeutics’ proprietary PTGR (Post-Transcriptional Gene Restoration) platform, protected by three international patent families, is designed to restore gene expression through targeted modulation of microRNA–mRNA interactions, with the potential to deliver multiple first-in-class therapeutics across genetic, respiratory, and other diseases driven by these regulatory mechanisms.
ACESO’s technology platform is designed to restore CFTR function through scientifically grounded approaches that address expression, stability, and mutation-class biology.
01 — Who we are
Bench → bedside
Why Today's Therapies Fall Short
Existing modulators fail to address rare and severe CFTR variants, leaving thousands without a viable therapy.
Many patients experience only modest improvement in lung function and quality of life on current treatments.
Lifetime treatment costs exceeding $300K per year per patient strain healthcare systems globally.
TECHNOLOGY PLATFORM
A scientifically grounded investment thesis, rooted in complementary mechanisms and validated mutation-class biology.
TECHNOLOGY 01
TECHNOLOGY 02
TECHNOLOGY 03
TECHNOLOGY 04
Programs designed to extend CFTR rescue across all mutation classes and rare genotypes.
Other indications : COPD and more please contact us
CASE STUDIES
ACADEMIC · SINCE 2021
A focused research partnership exploring complementary mechanisms to restore CFTR function for underserved cystic fibrosis mutation classes.
STRATEGIC · SINCE 2022
RESEARCH · SINCE 2023
A scientific collaboration designed to identify mutation-class opportunities and accelerate therapeutic strategies for patients with limited options.
PLATFORM-LED. SCIENCE-GROUNDED. PATIENT-FOCUSED.
Connect with ACESO to learn more about our technology platform, pipeline strategy, and commitment to advancing cystic fibrosis care.
